

# Accepted Manuscript

Synthetic cathinone MDPV downregulates glutamate transporter subtype I (GLT-1) and produces rewarding and locomotor-activating effects that are reduced by a GLT-1 activator

Ryan A. Gregg, Callum Hicks, Sunil U. Nayak, Christopher S. Tallarida, Paul Nucero, Allen B. Reitz, Garry R. Smith, Scott M. Rawls

PII: S0028-3908(16)30154-X

DOI: [10.1016/j.neuropharm.2016.04.014](https://doi.org/10.1016/j.neuropharm.2016.04.014)

Reference: NP 6266

To appear in: *Neuropharmacology*


Received Date: 25 November 2015

Revised Date: 18 March 2016

Accepted Date: 11 April 2016

Please cite this article as: Gregg, R.A., Hicks, C., Nayak, S.U., Tallarida, C.S., Nucero, P., Reitz, A.B., Smith, G.R., Rawls, S.M., Synthetic cathinone MDPV downregulates glutamate transporter subtype I (GLT-1) and produces rewarding and locomotor-activating effects that are reduced by a GLT-1 activator, *Neuropharmacology* (2016), doi: 10.1016/j.neuropharm.2016.04.014.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**Synthetic cathinone MDPV downregulates glutamate transporter subtype I (GLT-1) and produces rewarding and locomotor-activating effects that are reduced by a GLT-1 activator**

Ryan A. Gregg<sup>1,2</sup>, Callum Hicks<sup>1,2</sup>, Sunil U. Nayak<sup>1,2</sup>, Christopher S. Tallarida<sup>1,2</sup>, Paul Nucero<sup>1,2</sup>, Allen B. Reitz<sup>3</sup>, Garry R. Smith<sup>3</sup>, and Scott M. Rawls<sup>1,2</sup>

<sup>1</sup>Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA

<sup>2</sup>Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA

<sup>3</sup>Fox Chase Chemical Diversity Center, Doylestown, PA

**Corresponding Author:** Scott M. Rawls, Ph.D., Department of Pharmacology, Center for Substance Abuse Research, Temple University School of Medicine, 3500 North Broad Street, Philadelphia, PA, 19140, USA Tel: (215) 707-4942; Fax: (215) 707-7068; e-mail: [scott.rawls@temple.edu](mailto:scott.rawls@temple.edu)

**Funding Sources:** National Institute on Drug Abuse grants R01DA039139 and P30DA013429

Download English Version:

<https://daneshyari.com/en/article/5813462>

Download Persian Version:

<https://daneshyari.com/article/5813462>

[Daneshyari.com](https://daneshyari.com)